(Circulation. 1995;92:1079-1082.)
© 1995 American Heart Association, Inc.
Articles |
Calcium Antagonists in Coronary Artery Disease and Hypertension
Time For Reevaluation?
From the Division of Cardiology, McMaster University, and Cardiovascular Therapeutics and Research Program, Hamilton Civic Hospitals Research Centre, Hamilton General Hospital, Ontario, Canada.
Correspondence to Dr Salim Yusuf, Hamilton Civic Hospitals Research Centre, Hamilton General Hospital, 237 Barton St E, Hamilton, Ontario L8L 2X2, Canada. Email yusufs@fhs.csu.mcmaster.ca.
 |
Introduction |
|---|
Calcium antagonists have been used in patients with cardiovascular diseases for about 2 decades. Regulatory authorities have approved the use of calcium antagonists in individuals with angina pectoris to relieve chest pain or with hypertension to lower blood pressure. As a class, they are among the most widely used drugs for treatment of cardiovascular conditions. Numerous randomized placebo-controlled studies have demonstrated the value of these agents for relieving symptoms in patients with angina, an action generally associated with increased exercise tolerance in formal exercise testing. However, no study in which a calcium antagonist was used in stable angina pectoris or other clinical manifestations of coronary artery disease has yet to demonstrate convincingly a reduction in morbidity (eg, reinfarction or stroke) or mortality. In part, this gap in our information may be because few large, long-term clinical trials have been designed to test these questions and perhaps because relief of angina per se is a worthwhile goal of therapy in symptomatic patients. However, data accumulated from clinical trials conducted over the last decade have raised concerns as to whether some or all of the calcium antagonists increase morbidity (eg, worsen unstable angina,1 increase heart failure,2 or increase the risk of infarction3 ) and mortality.4 These data on the potential adverse effects of calcium antagonists have been obtained from patients who have a variety of clinical manifestations of coronary artery disease, including stable angina pectoris,5 unstable angina,1 6 and acute myocardial infarction (MI),7 during long-term use after MI,7 and heart failure.8 Patients who
This article has been cited by other articles:
 |
|
 |
|
  A. M. Dart, J. E. Otterstad, B.-A. Kirwan, J. D. Parker, S. de Brouwer, P. A. Poole-Wilson, and J. Lubsen Predictive value of local and core laboratory echocardiographic assessment of cardiac function in patients with chronic stable angina: The ACTION study Eur J Echocardiogr, August 1, 2007; 8(4): 275 - 283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-Y. Min, A. Meissner, J. Wang, and J. P. Morgan Mibefradil Improves {beta}-Adrenergic Responsiveness and Intracellular Ca2+ Handling in Hypertrophied Rat Myocardium Experimental Biology and Medicine, May 1, 2002; 227(5): 336 - 344. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lin, Z. Wang, and D. Fedida Influence of permeating ions on Kv1.5 channel block by nifedipine Am J Physiol Heart Circ Physiol, March 1, 2001; 280(3): H1160 - H1172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Grace and A.J. Camm Voltage-gated calcium-channels and antiarrhythmic drug action Cardiovasc Res, January 1, 2000; 45(1): 43 - 51. [Full Text] [PDF]
|
|
|
|
 |
|
 J.-Y. Min, S. Sandmann, A. Meissner, T. Unger, and R. Simon Differential Effects of Mibefradil, Verapamil, and Amlodipine on Myocardial Function and Intracellular Ca2+ Handling in Rats with Chronic Myocardial Infarction J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 1038 - 1044. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. R. Abernethy and J. B. Schwartz Calcium-Antagonist Drugs N. Engl. J. Med., November 4, 1999; 341(19): 1447 - 1457. [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Jollis, R. J. Simpson Jr, M. K. Chowdhury, W. E. Cascio, J. R. Crouse III, M. W. Massing, and S. C. Smith Jr Calcium Channel Blockers and Mortality in Elderly Patients With Myocardial Infarction Arch Intern Med, October 25, 1999; 159(19): 2341 - 2348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Meissner, J.-Y. Min, N. Haake, S. Hirt, and R. Simon Dantrolene sodium improves the force-frequency relationship and {beta}-adrenergic responsiveness in failing human myocardium Eur J Heart Fail, June 1, 1999; 1(2): 177 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. M. Abascal, M. G. Larson, J. C. Evans, A. T. Blohm, K. Poli, and D. Levy Calcium Antagonists and Mortality Risk in Men and Women With Hypertension in the Framingham Heart Study Arch Intern Med, September 28, 1998; 158(17): 1882 - 1886. [Abstract] [Full Text]
|
|
|
|
 |
|
 X. Zhang and D. Fedida Potassium Channel–Blocking Actions of Nifedipine: A Cause for Morbidity at High Doses? Circulation, May 26, 1998; 97(20): 2098 - 2098. [Full Text]
|
|
|
|
|
|
S. Richard, F. Leclercq, S. Lemaire, C. Piot, and J. Nargeot Ca2+ currents in compensated hypertrophy and heart failure Cardiovasc Res, February 1, 1998; 37(2): 300 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. T. Stelfox, G. Chua, K. O'Rourke, and A. S. Detsky Conflict of Interest in the Debate over Calcium-Channel Antagonists N. Engl. J. Med., January 8, 1998; 338(2): 101 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ishikawa, S. Nakai, T. Takenaka, K. Kanamasa, J. Hama, I. Ogawa, T. Yamamoto, M. Oyaizu, A. Kimura, K. Yamamoto, et al. Short-Acting Nifedipine and Diltiazem Do Not Reduce the Incidence of Cardiac Events in Patients With Healed Myocardial Infarction Circulation, May 20, 1997; 95(10): 2368 - 2373. [Abstract] [Full Text]
|
|
|
|
|
|
J. A. Ambrose and M. Weinrauch Thrombosis in Ischemic Heart Disease Arch Intern Med, July 8, 1996; 156(13): 1382 - 1394. [Abstract] [PDF]
|
|
|
|
|
|
T. C. Fagan Calcium Antagonists and Mortality: Another Case of the Need for Clinical Judgment Arch Intern Med, November 13, 1995; 155(20): 2145 - 2145. [Abstract] [PDF]
|
|
|
|
 |
|
 More Worrisome Findings About a Calcium Blocker Journal Watch Cardiology, October 1, 1995; 1995(1001): 19 - 19. [Full Text]
|
|
|
|
 |
|
 MORE WORRISOME FINDINGS ABOUT A CALCIUM BLOCKER Journal Watch (General), September 8, 1995; 1995(908): 1 - 1. [Full Text]
|
|